Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.

doi:10.1002/jmv.26383

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.

Journal of medical virology - 1 Dec 2020

Ridruejo Ezequiel, Piñero Federico, Mendizabal Manuel, Cheinquer Hugo, Wolff Fernando Herz, Anders Margarita, Reggiardo Virginia, Ameigeiras Beatriz, Palazzo Ana, Alonso Cristina, Schinoni María Isabel, Zuain María Grazia Videla, Tanno Federico, Figueroa Sebastián, Santos Luisa, Peralta Mirta, Soza Alejandro, Vistarini Cecilia, Adrover Raúl, Fernández Nora, Perez Daniela, Hernández Nelia, Estepo Claudio, Bruno Andres, Descalzi Valeria, Sixto Marcela, Borzi Silvia, Cocozzella Daniel, Zerega Alina, de Araujo Alexandre, Varón Adriana, Silva Marcelo

Abstract excerpt

INTRODUCTION: Although the effectiveness of direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus (HCV) has been reported in real-world settings, predictive factors of treatment failure are lacking. Therefore, we sought to explore the baseline predictors of treatment response to DAAs. METHODS: This was a prospective multicenter cohort study from the Latin American Liver Research...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Latin America

Share to Liver Cirrhosis

Share to Liver Transplantation

Share to Ribavirin

Share to Sustained Virologic Response

Share to Treatment Failure

Source

Open in PubMed

Identifiers

PMID: 32749710
DOI: 10.1002/jmv.26383

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.PMID 32749710Read ↗

Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis.Semantic proximity Read ↗

Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.Semantic proximity Read ↗

Efficacy of Sofosbuvir-Velpatasvir-Ribavirin Regimen for Retreatment of Chronic Hepatitis C in Patients with Prior DAA Failure: A Retrospective Study from a National Treatment CenterSemantic proximity Read ↗

Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study.Semantic proximity Read ↗

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Semantic proximity Read ↗

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.Semantic proximity Read ↗

Early post-liver transplant use of direct-acting antivirals in naive and NS5A inhibitor-experienced HCV patients.Semantic proximity Read ↗

100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.Semantic proximity Read ↗

Treatment Failure with Direct Antiviral Agents in Patients with Hepatitis C Virus Genotype 1 Infection at the Veteran Affairs Caribbean Healthcare System in San Juan, Puerto Rico.Semantic proximity Read ↗

Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.Semantic proximity Read ↗

Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.Semantic proximity Read ↗

Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.